IRulya Therapeutics Inc. IRLA
38.33 USD -0.29 (-0.75%)
At closeNov 11, 2026, 4:00 PM EST
38.33 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
38.33 Day range 45.00
15.10 52-week range 910.00
- YTD
- -94.28%
- 1 year
- -89.29%
- Market cap
- 415.55M
- EPS (ttm)
- -214.01
- YTD return
- -94.28%
- 1-year return
- -89.29%
- Volume
- 156.49K
- Avg volume
- 48.78K
- Open
- 38.62
- Previous close
- 38.62
- Day's range
- 38.33 – 45.00
- 52-week range
- 15.10 – 910.00
5D +4.47 (+13.09%)
Financials — quick view
IRLA Revenue — quarterly 0
IRLA Net income — quarterly -75.49M
IRLA EPS — quarterly -12.31
News
IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference 
Quince Therapeutics (NASDAQ: QNCX) renames itself IRulya and sets IRLA ticker 
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease 
Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity Plans 
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript 
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript 
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026 
Quince Therapeutics to Participate in September 2026 Investor Conferences
Your note
Sign in to keep a note on IRLA — it syncs with the Stock Master app.